FDA has approved and expanded the age indication for Zoster Vaccine Live, (Zostavax, Merck) for the prevention of herpes zoster, commonly known as shingles, in adults ages 50 years and older. Zostavax was first approved in May 2006 for the prevention of shingles in individuals aged 60 years and older. Zostavax is the only shingles vaccine licensed for use in the United States. According to the US Centers for Disease Control and Prevention, approximately 1 in 3 people will experience shingles in their lifetime and nearly 1 million cases of shingles occur each year, and the incidence and severity of shingles increase with age. Zostavax is not indicated for the treatment of shingles or postherpetic neuralgia, or for the prevention of chickenpox. Zostavax is contraindicated for individuals who are allergic to any of its ingredients, including gelatin or neomycin; have a weakened immune system; or take high doses of steroids. It is also contraindicated for individuals who are pregnant or plan to become pregnant. Vaccination with Zostavax may not result in protection of all vaccine recipients. Zostavax is currently on back order.
